Weekly-Round-Up-July-25th to July-31st
August 01, 2022
National direct primary care provider Everside Health has secured $164 million in growth equity capital.
All former Everside investors, including Oak HC/FT and Alta Partners, and nine new investors, including Endeavor Catalyst, joined long standing investor New Enterprise Associates, Inc. (NEA), a worldwide venture capital firm that invests in transformational healthcare and technology firms.
A $12.9 million Series A funding has been completed by Rush ReCommerce, a recommerce software and service provider. With participation from current stockholders and Advantage Capital, Beringea led the round.
Elation Health, the clinical-first technology business driving primary care innovation, announced a $50 million Series D fundraising round.
Threshold Ventures, Ascend Partners, and individual investors like Fay Rotenberg and Jonathan Bush joined Ascension Ventures in co-leading the round with Generation Investment Management, a company founded in 2004 to support companies advancing sustainability.
Underdog, the paid fantasy sports company with the fastest growth rate ever, released information about a Series B investment round.
The $35 million deal values the company at $485 million and comprises Acies Investment as well as assets and accounts managed by BlackRock (BlackRock).
PunchListUSA, a real estate platform that digitizes data from house inspections for rapid quotes and online ordering of home repair services, has received $39 million in investors, with Sweetwater Private Equity and Morpheus Ventures leading the charge.
Vicinitas Therapeutics, a biotechnology firm building a tailored protein stabilizationplatform to create innovative cancer and genetic condition treatments, announced the closing of a $65 million Series A fundraising round. Along with Droia Ventures, GV, The Mark Foundation for Cancer Research, and Berkeley Catalyst Fund, the funding was co-led by a16z and Deerfield Management.
A novel biotechnology startup called Novasenta has completed a $40 million Series A funding headed by UPMC Enterprises. The company focuses on the identification and validation of innovative targets for the development of cancer therapies.